Dr. Diane M. Harper, a lead researcher from Dartmouth Medical School in New Hampshire has called the results of a vaccination trial against the Human Papilloma Virus (HPV) “extremely exciting and encouraging”. A simple vaccination against this virus, which is the cause for cancer of the cervix, has the potential to eradicate the vast majority of cervical cancers worldwide.
The injection in the study was tested on 1,113 women between the ages 15 and 25 over an 18-month period. One hundred percent of the patients of the vaccinated group escaped persistent infection.
The protection against initial HPV- infection was at 92 %.
At this point a much larger trial is set to begin, before the vaccination can be licensed for general use. It will very likely soon be a routine vaccination for young women. If it is successful, it will be a powerful tool for prevention and will save thousands of lives that otherwise would be lost to cervical cancer. Even for those patients who dread shots, a needle prick will be a small price to pay.
More info on cervical cancer: http://nethealthbook.com/cancer-overview/cervical-cancer/
Comment on Nov. 7, 2012: In the meantime the vaccine has been introduced into the school vaccination program of many countries around the world, but mostly concentrating on the female population. In Australia the vaccine is given to boys aged 9 to 15 and girls. The two main brand names are Gardasil and Cervarix. Here is a detailed medical review from Great Britain.
Last edited October 27, 2014